Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of Schedule-Modulated Concomitant Pemetrexed (Alimta) and Erlotinib (Tarceva) vs Single Agent Pemetrexed (Alimta®) in Patients With Progressive or Recurrent Non-small Cell Lung Cancer (NSCLC)

NCT00950365 is registered in ClinicalTrials.gov with Albert Einstein College of Medicine as lead sponsor.

NCT NCT00950365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00950365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of Schedule-Modulated Concomitant Pemetrexed (Alimta) and Erlotinib (Tarceva) vs Single Agent Pemetrexed (Alimta®) in Patients With Progressive or Recurrent Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
Albert Einstein College of Medicine
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2006
Completion date
November 17, 2017
Enrollment
79 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

bronchioloalveolar carcinoma, large cell lung carcinoma, lung adenocarcinoma, recurrent non-small cell lung carcinoma, stage iiib non-small cell lung cancer, stage iv non-small cell lung cancer